Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Employees

372

Sector

Pharmaceuticals

Calendar

13/02/2025 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
10/02/25	981.00 ¥	-0.20%	451,200
07/02/25	983.00 ¥	+2.18%	733,800
06/02/25	962.00 ¥	+1.80%	515,800
05/02/25	945.00 ¥	-0.53%	524,200
04/02/25	950.00 ¥	-0.21%	437,800

Delayed Quote Japan Exchange, February 10, 2025 at 06:30 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

BBB

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

983.00JPY

Average target price

2,090.00JPY

Spread / Average Target

+112.61%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 06:30:00 10/02/2025 GMT			5-day change	1st Jan Change
981.00 ^JPY	-0.20%		+1.24%	-6.39%

01-15	Nxera Pharma Co., Ltd. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:00 PM
12-05	Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea	CI

Capitalization	88.37B 584M 565M 531M 471M 837M 51.25B 933M 6.39B 2.37B 21.03B 2.19B 2.15B	P/E ratio 2024 *	-48.9x	P/E ratio 2025 *	62x
Enterprise value	107B 709M 686M 645M 572M 1.02B 62.2B 1.13B 7.75B 2.88B 25.52B 2.66B 2.61B	EV / Sales 2024 *	3.06x	EV / Sales 2025 *	2.31x
Free-Float	90.56%	Yield 2024 *	-	Yield 2025 *	-

Nxera Pharma Co., Ltd. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:00 PM	01-15
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea	12-05	CI
Nikkei Slips as Beijing's Property Support Measures Fail to Lift Sentiment	11-14	MT
Nxera Pharma's Partner Centessa Launches Phase 2 Trial of ORX750	11-13	MT
Nxera Pharma Co., Ltd. - Special Call	11-06
Nxera Pharma and Antiverse Enter Collaboration to Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI	11-05	CI
Japanese Shares Drop as Investors Seek Safety Amid Middle East Tensions	02/10/24	MT
Nxera Pharma Partners with Shionogi to Market Insomnia Drug QUVIVIQ in Japan	02/10/24	MT
Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma	01/10/24	CI
Nxera Pharma to Receive $35M Milestone Payment for Schizophrenia Drug	03/09/24	MT
Nxera Pharma Co., Ltd. to Receive USD 35 Million from Neurocrine Biosciences Upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568	02/09/24	CI
Nxera, Neurocrine Report Positive Phase 2 Results for Schizophrenia Drug	29/08/24	MT
Nxera Pharma Co., Ltd. - Special Call	28/08/24

Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18/04/24	MT
Jefferies Adjusts Sosei Group’s Price Target to 2,100 Yen From 1,800 Yen, Keeps at Buy	12/03/24	MT
Jefferies Adjusts Sosei Group's Price Target to 1,800 Yen From 1,700 Yen, Keeps at Buy	25/01/24	MT
Jefferies Upgrades Sosei to Buy From Hold, Adjusts Price Target to 1,700 Yen From 1,600 Yen	30/11/23	MT
Jefferies Downgrades Sosei Group Corporation to Underperform From Buy, Adjusts Price Target to 1,800 Yen From 4,200 Yen	27/06/23	MT

Nxera Pharma Co., Ltd. Share Price

Equities

4565

JP3431300007

Pharmaceuticals

Valuation: Nxera Pharma Co., Ltd.

Chart: Nxera Pharma Co., Ltd.

Latest news: Nxera Pharma Co., Ltd.

Last Transcript: Nxera Pharma Co., Ltd.

Analysts' recommendations: Nxera Pharma Co., Ltd.

Press Releases: Nxera Pharma Co., Ltd.

News in other languages: Nxera Pharma Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Nxera Pharma Co., Ltd.

ETFs: Nxera Pharma Co., Ltd.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Nxera Pharma Webinar Presentation for FY2024 Financial Results	01-23	AQ
Nxera Pharma : Corporate Presentation (Corporate Presentation 2025Jan EN v2)	01-22	PU
Nxera Pharma : Corporate Presentation (Corporate Presentation 2025Jan EN v1)	01-17	PU
Nxera Pharma : 43rd Annual J.P. Morgan Healthcare Conference (2025.1.15 JPM Presentation EN v7)	01-15	PU
Nxera Pharma : Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio	01-14	PU

Idorsia perçoit 350 millions de dollars pour les sélatogreé et cénérimod	18/03/24
Idorsia cède encore des programmes en échange de financements	28/02/24
Idorsia: la restructuration passera par 300 licenciements	24/10/23
Idorsia revoit ses pertes à la baisse pour 2023	24/10/23
Idorsia dämmt Verlust in ersten neun Monaten ein	24/10/23

1 day	-0.20%
1 week	+3.05%
Current month	+1.24%
1 month	-0.51%
3 months	-17.84%
6 months	-37.20%
Current year	-6.39%

Director	Title	Age	Since
Chris Cargill CEO	Chief Executive Officer	41	23/03/2022
Hironoshin Nomura DFI	Director of Finance/CFO	41	23/03/2022
Toshihiro Maeda COO	Chief Operating Officer	-	30/11/2023

Manager	Title	Age	Since
Shinichi Tamura CHM	Chairman	75	23/06/2016
Tomohiro Toyama BRD	Director/Board Member	75	31/05/2011
Chris Cargill BRD	Director/Board Member	41	23/03/2022

Name	Weight	AuM	1st Jan change	Investor Rating
SIMPLEX TSE GROWTH CORE ETF - JPY	7.92%	24 M€	+4.40%
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	0.55%	20 M€	-5.28%
MAXIS TOPIX ETF - JPY	0.03%	21,019 M€	-2.86%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NXERA PHARMA CO., LTD.	-0.20%	+3.05%	-28.65%	-35.97%	584M
CSL LIMITED	+0.18%	-1.83%	-6.86%	+6.55%	81.84B
SAMSUNG BIOLOGICS CO.,LTD.	+6.52%	+16.00%	+42.33%	+50.06%	56.82B
UCB	-0.26%	+1.56%	+99.68%	+116.10%	37.13B
BIOGEN INC.	-0.72%	-1.79%	-41.34%	-37.68%	20.6B
ALTEOGEN INC.	-0.13%	+5.38%	+409.77%	+826.63%	14.36B
INCYTE CORPORATION	-1.09%	-0.04%	+28.56%	+8.57%	14.28B
INTRA-CELLULAR THERAPIES, INC.	-0.09%	-0.06%	+74.54%	+141.69%	13.49B
BIOMARIN PHARMACEUTICAL INC.	-0.64%	+0.90%	-27.73%	-30.90%	12.18B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-0.22%	-0.34%	+8.13%	-40.85%	11.78B
Average	+0.33%	+1.34%	+55.84%	+100.42%	26.31B
Weighted average by Cap.	+1.26%	+0.65%	+44.60%	+75.80%

	2024 *	2025 *
Net sales	35.08B 232M 224M 211M 187M 332M 20.34B 370M 2.54B 942M 8.35B 870M 852M	37.34B 247M 239M 225M 199M 354M 21.66B 394M 2.7B 1B 8.88B 926M 907M
Net income	-1.64B -10.88M -10.52M -9.89M -8.77M -15.57M -954M -17.37M -119M -44.19M -391M -40.78M -39.95M	1.43B 9.47M 9.16M 8.61M 7.64M 13.57M 831M 15.13M 104M 38.49M 341M 35.52M 34.8M
Net Debt	18.88B 125M 121M 114M 101M 179M 10.95B 199M 1.36B 507M 4.49B 468M 459M	-1.93B -12.79M -12.37M -11.63M -10.32M -18.32M -1.12B -20.42M -140M -51.97M -460M -47.96M -46.99M